River blindness is a parasitic disease caused by a worm called Onchocerca volvulus that spreads through the bites of blackflies. It gets its name from two facts: the blackflies that transmit it breed near fast-flowing rivers, and the infection can permanently destroy vision. The disease primarily affects communities in sub-Saharan Africa, with smaller pockets in parts of Latin America and Yemen, and it remains one of the leading infectious causes of blindness worldwide.
How the Infection Spreads
Blackflies in the genus Simulium are the sole carriers of the parasite. These flies depend on fast-moving water to reproduce. Their larvae develop in rivers and streams, which is why communities living and farming near waterways face the highest risk. When an infected blackfly bites a person, it deposits microscopic larvae onto the skin. Those larvae burrow in, mature into adult worms over the course of about a year, and can then live inside the body for 10 to 15 years.
Once mature, adult worms pair up and produce millions of tiny offspring called microfilariae. These microfilariae migrate through the skin and eyes, and when another blackfly bites the infected person, it picks up the larvae and carries them to the next host. The cycle repeats wherever blackflies and human populations overlap along river systems.
What It Does to the Body
The adult worms themselves cause relatively little direct harm. They coil together inside firm, painless nodules under the skin, often around the hips, torso, and head. The real damage comes from the microfilariae, which number in the hundreds of millions over the course of a long infection.
The most common symptom is intense, relentless itching. This isn’t mild discomfort. People with heavy infections scratch constantly, sometimes to the point of open wounds and secondary bacterial infections. Over time, the skin itself changes. Chronic inflammation can cause it to lose its color in patches (sometimes called “leopard skin”), become thin and papery, and lose elasticity. In severe cases, the skin around the groin can stretch and sag, a condition known as “hanging groin.”
How It Causes Blindness
The microfilariae don’t stay in the skin. They migrate into the eyes, and when they die there, the body’s immune system attacks the dead organisms. That inflammatory response is what destroys vision. Each dying microfilaria triggers a small focal reaction in the cornea, visible under a microscope as a tiny white spot sometimes called a “snowflake” lesion. One episode heals. But with thousands of microfilariae dying in the eyes over years, the repeated cycles of inflammation and healing gradually build up scar tissue across the cornea.
The scarring typically starts at the edges of the cornea and works inward, progressively narrowing the field of clear vision until it’s gone entirely. Research has shown that a bacterium living inside the worm, called Wolbachia, plays a central role in amplifying this immune response. When microfilariae die, the Wolbachia they carry are released into surrounding tissue, intensifying the inflammation far beyond what the dead worm alone would cause. This is why the blindness develops so aggressively in heavily infected people.
Diagnosis
The standard test is a skin snip biopsy. A clinician uses a small punch tool or a needle and scalpel to remove a tiny piece of skin, about 3 millimeters across. That sample is placed in saline solution and left at room temperature for 24 hours. During that time, any microfilariae present will wriggle out of the tissue and can be identified under a microscope. Samples are typically taken from several body sites (the hip, shoulder blade, and lower legs) because six snips provide the best sensitivity.
For people with eye symptoms, a slit lamp exam can reveal microfilariae moving in the front chamber of the eye or show the corneal lesions they’ve caused. Blood-based antibody tests exist but are mostly limited to research settings. A more sensitive molecular test (PCR) can be run on skin snip samples to detect low-level infections, though it isn’t widely available in the field.
Treatment
The primary treatment is ivermectin, donated globally under the brand name Mectizan. It kills the microfilariae but not the adult worms, so it doesn’t cure the infection in a single dose. Instead, it’s taken once a year (or in some programs, twice a year) for the entire lifespan of the adult worms, which can be well over a decade. The drug has minimal side effects for most people and doesn’t require close medical supervision, which makes it practical for mass distribution in remote areas.
Each dose dramatically reduces the number of microfilariae in the skin and eyes, which slows or halts the progression of skin disease and vision loss. It also reduces the chance that a blackfly picking up larvae from a treated person can pass the infection along. In communities where nearly everyone takes the drug annually, transmission can eventually be interrupted altogether.
If a person has visible nodules, surgical removal (nodulectomy) is sometimes performed. This eliminates the adult worms inside the nodule and confirms the diagnosis. It’s a minor procedure but isn’t practical as a standalone treatment since not all adult worms form nodules close enough to the surface to find.
Prevention and Control
Because the disease depends entirely on blackflies, controlling the fly population has been a cornerstone of prevention for decades. The most effective large-scale method is larviciding: spraying insecticides into the rivers and streams where blackfly larvae develop. In West Africa, aerial spraying campaigns treated vast stretches of river systems, dramatically reducing blackfly populations across entire regions. Ground-based treatments, using handheld sprayers or boats, supplement aerial operations in harder-to-reach areas or where fly populations are lower.
For individuals, avoiding blackfly bites is the goal. The flies bite during the day, particularly near rivers, so wearing long sleeves and using insect repellent with DEET helps reduce exposure. But personal protection alone can’t eliminate the disease from a community. The combination of mass ivermectin distribution and vector control is what has driven river blindness toward elimination in several countries.
Where River Blindness Still Occurs
The vast majority of cases are concentrated in sub-Saharan Africa, particularly in countries along major river basins in West, Central, and East Africa. Smaller endemic areas exist in Yemen and in parts of Latin America, though several Latin American countries have successfully interrupted transmission through sustained treatment campaigns.
The World Health Organization’s targets for elimination require near-zero evidence of ongoing transmission: less than 0.1% antibody positivity in children under 10 (indicating they haven’t been exposed) and less than 0.05% infection rates in wild-caught blackflies. Meeting those thresholds means the parasite has essentially vanished from both human and insect populations in a given area, and treatment can safely stop without the disease bouncing back.
Reaching that goal across all of Africa remains a massive challenge. In areas with high baseline infection rates, models suggest that decades of sustained annual treatment are needed before transmission drops low enough to qualify. Communities near large, fast-flowing rivers where blackfly populations are dense face the steepest climb, since even small gaps in treatment coverage can allow the cycle to restart.